Latest news with #U.SFoodandDrugAdministration
The Hindu
29-07-2025
- Business
- The Hindu
Agilent Tech opens Biopharma Experience Centre in Hyderabad
NYSE-listed global leader in Life Sciences, diagnostics and applied chemical markets Agilent Technologies has established a Biopharma Experience Centre in Hyderabad to support the drug development journey of its customers. End-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis and lab informatics that will allow its customers to simulate real lab environments are available. The companies can test for quality and compliance and co-create market-ready solutions, Industries and IT Minister Babu's office said after he inaugurated the facility on Tuesday. Launch of the facility is a significant milestone in strengthening Telangana's position as a global leader in Life Sciences and a valuable addition to expanding innovation-driven ecosystem, the Minister said. Rounded ecosystem Hyderabad has emerged as a complete healthcare and life sciences ecosystem, from contributing to drug discovery and clinical trials to playing host to world-class hospitals and affordable, high-quality patient care. 'We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains and over 230 U.S Food and Drug Administration (U.S FDA)-approved manufacturing facilities,' Babu said. Telangana contributes nearly one-third of India's pharmaceutical production and 40% of bulk drug exports from the country. 'With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system,' he said. Agilent's new facility is poised to serve as a hub for innovation and collaboration, supporting development of biologics, biosimilars and precision medicine, the Minister's office said. 'India is a strategic growth market for Agilent,' Agilent president and CEO Padraig McDonnell said. Serving as foundation for the new centre is Hyderabad's mature and future-focused life sciences ecosystem that thrives on deep industry expertise, strong research and development capabilities and a supportive policy environment. With its legacy in generics and a focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. Without mentioning either the investment or hiring plans, Agilent said its capital investment in the facility is part of a broader three-to-five-year India growth strategy. The India Solution Centre in Manesar launched earlier this year further is a reflection of its commitment to enhance presence and capabilities in one of its fastest-growing, high-priority markets globally.
The Hindu
28-06-2025
- Health
- The Hindu
Aurobindo Pharma arm recalling 48,000 vials of Gentamicin Injection in U.S.
Eugia US LLC, a step down subsidiary of Hyderabad-headquartered generic drugmaker Aurobindo Pharma, is recalling 48,000 vials of Gentamicin Injection paediatric doses from the U.S. The Gentamicin Injection, USP, (paediatric), 20 mg per 2 mL, 2 mL Single-Dose Vial are manufactured in India, the latest enforcement report of the U.S Food and Drug Administration showed. The injections are being recalled as a result of failed stability specifications - out of specification results for the colour absorbance test during 12 month sample analysis, the regulator said. It is a voluntary recall and initiated by the company on May 29. Gentamicin is an antibiotic and used to treat bacterial infections.
Business Standard
12-06-2025
- Business
- Business Standard
Zydus Life receives USFDA EIR for Gujarat facility
Zydus Lifesciences has informed that it has received the establishment inspection report (EIR) from the U.S Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) manufacturing facility located in Ankleshwar, Gujarat. The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the review, the inspection has been classified as no action indicated (NAI). The USFDA has concluded that the inspection is now closed. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences shed 0.36% to Rs 975.20 on the BSE.
Business Standard
09-06-2025
- Business
- Business Standard
Lupin gets USFDA nod for Oxcarbazepine ER tablets
Lupin announced that it has received tentative approval from the U.S Food and Drug Administration (US FDA) for its abbreviated new drug application for Oxcarbazepine extended-release (ER) tablets. Oxcarbazepine ER tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR ER tablets, 150 mg, 300 mg, and 600 mg, of Supernus Pharmaceuticals, Inc., and are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. This product would be manufactured at Lupins Nagpur facility in India. Oxcarbazepine ER tablets (RLD Oxtellar XR) had estimated annual sales of $206 million in the U.S. (IQVIA MAT April 2025). Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.20% to end at Rs 1,999.20 on the BSE.
Yahoo
21-05-2025
- Business
- Yahoo
Ziploc Is Being Sued Over Claims Its Bags Release Harmful Microplastics Into Food
Earlier this year, the U.S Food and Drug Administration (FDA) announced a ban on Red No. 3 in food and drinks, a move many felt was a step in the right direction regarding industry standards. Not long after, however, the FDA announced it would be temporarily halting its milk testing program, a change that drew criticism from food safety experts. Now, as grocery prices continue to rise, consumers are paying more attention than ever to their shopping carts. Recently, a class action lawsuit was filed against Wheat Thins, accusing the brand of misrepresenting its ingredients. Now, a popular storage bag brand is under fire after allegedly failing to disclose the risks of its products. On April 25, 2025, a lawsuit was filed against Ziploc, an S.C. Johnson-owned brand. The lawsuit, filed by Linda Cheslow, alleges that certain Ziploc bags are labeled as 'microwave safe' and suitable for 'freezer' use, giving shoppers the impression they were safe to use in those ways. Cheslow, however, believes the brand is misleading customers and putting them at risk for microplastic consumption. An issue, the plaintiff says, is made worse by Ziploc's claim that its products are reusable. 'These products are made from polyethylene and polypropylene—materials that scientific and medical evidence shows release microplastics when microwaved and frozen—making them fundamentally unfit for microwave and freezer use,' reads page four of the lawsuit document. Polyethylene and polypropylene are two common food-grade plastic materials used in the production of kitchen goods, including cutting boards, storage containers, and cling wrap, to name a few. When exposed to extreme temperatures, such as heat or cold, they have been found to release microplastics, which can leach into food. Microplastics, while invisible to the naked eye, have been linked to a variety of health concerns, including increased cancer risk, immune dysfunction, and inflammation. Cheslow believes that the company is putting families at risk by failing to disclose this information, and it's doing so 'for profit and to gain an unfair competitive edge in the marketplace.' S.C. Johnson has denied these claims, and litigation is ongoing. This is a class action lawsuit, meaning that it was filed on behalf of all who have purchased the product. At this time, there is no action consumers need to take. In the future, you may be able to file a claim and receive a monetary reward if a settlement fund is established. The products in question include, but are not limited to: Ziploc Freezer Bags Pint Ziploc Freezer Bags Quart Freezer Bags Gallon Ziploc Slider Freezer Bags Quart Ziploc Slider Freezer Gallon Ziploc Slider Storage Bags Quart Ziploc Slider Storage Bags Gallon Ziploc Containers Additionally, consumers may find photos of the products beginning on page nine of the lawsuit documents. Be sure to take note of which products are included when you compile your receipts and stay up to date as the case proceeds. Read the original article on ALLRECIPES
